Karuna Therapeutics, Inc. KRTX
329.83 +329.83
Day range unavailable
52-week range unavailable
Financial health
Altman Z-Score
91.14 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Valuation
P/E -27.0×
FY 2017 5y median -26.5× FY 2023
P/S 17887×
FY 2017 5y median 103× FY 2023
P/B 9.3×
FY 2017 5y median 7.6× FY 2023
P/FCF -30.1×
FY 2017 5y median -30.1× FY 2023
EV/EBITDA -23.4×
FY 2017 5y median -23.4× FY 2023
EV/Sales 17628×
FY 2017 5y median 97.9× FY 2023
FCF Yield -3.3%
FY 2017 5y median -3.3% FY 2023
Profitability
Gross Margin -160.1%
FY 2017 5y median 0.0% FY 2023
Operating Margin -75654.0%
FY 2017 5y median -389.2% FY 2023
Net Margin -66311.9%
FY 2017 5y median -389.0% FY 2023
ROE -34.6%
FY 2017 5y median -24.5% FY 2023
ROIC -38.9%
FY 2017 5y median -25.6% FY 2023
ROA -32.5%
FY 2017 5y median -23.8% FY 2023
Growth (YoY)
Revenue -93.9%
FY 2017 FY 2023
Operating Income -70.8%
FY 2017 FY 2023
EPS (diluted) -34.2%
FY 2017 FY 2023
Free Cash Flow -69.8%
FY 2017 FY 2023
Financial Health
Current Ratio 19.3×
FY 2017 5y median 34.0× FY 2023
Quick Ratio 18.8×
FY 2017 5y median 34.0× FY 2023
Debt / Equity 0.0×
FY 2017 5y median 0.0× FY 2023
Net Debt / EBITDA 0.3×
FY 2017 5y median 0.9× FY 2023
Interest Coverage 0.0×
FY 2017 5y median 0.0× FY 2023
Dividends
Dividend Yield 0.0%
FY 2017 5y median 0.0% FY 2023
Payout Ratio 0.0%
FY 2017 5y median 0.0% FY 2023
Annual · latest fiscal year ends 2023-12-31
